
Enabling rapid and sensitive GPCR assay development with the MaxCyte[®] STX[™] Scalable Transfection System and the Codex **ACTOne biosensor technology.**

James Brady¹, Jimmy Lu², Rama Shivakumar¹, Angelia Viley¹, Madhusudan Peshwa¹, Karen Donato¹, and Krista Steger¹. ¹MaxCyte Inc., Gaithersburg, MD, USA. ²Codex BioSolutions, Inc., Gaithersburg, MD USA

Abstract

The MaxCyte STX Scalable Transfection System, which is based on a proprietary flow electroporation technology, provides a labor and cost saving alternative to generating stable cell lines for screening a variety of drug targets, including GPCRs. Up to 1e10 cells can be transfected with plasmid DNA, mRNA siRNA, protein or other molecules in less than 30 minutes yielding viability and efficiency levels that exceed 90% with most cell types. The ACTOne[™] platform is based upon a modified cyclic nucleotide-gated (CNG) ion channel that serves as a biosensor of cAMP activity in live cells, allowing sensitive detection of signaling by Gs, Gi or Gq-coupled receptors. Here we demonstrate that the STX system enables rapid development of cell-based GPCR assays by transfecting cells with the ACTOne CNG channel. Transfecting the CNG channel by itself allowed detection of multiple endogenous receptors in HEK cells. Cotransfecting the CNG channel with GPCR expression plasmids yielded assay performance comparable to stable cell lines. Finally, assay scale up and cryopreservation of transfected cells were performed to illustrate that the MaxCyte STX System combined with the ACTOne Biosensor technology provide a rapid, flexible and economical alternative to stable cell line production for screening GPCRs.





to cAMP ELISA.






Figure 3. Rapid, small-scale GPCR assay development in HEK cells. HEK 293H cells were transfected in OC-100 processing assemblies with 3 different concentrations of plasmid

absence of DNA.



Correspondence: Jim Brady at jamesb@maxcyte.com



Moxcyte[®]

TRANSFECTION SYSTEMS

Figure 6. Transfecting HEK cells with the ACTOne Biosensor CNG plasmid at large-scale via flow electroporation. 3E8 HEK cells were suspended in 10 mL of MaxCyte's electroporation containing 100 µg/mL of a plasmid encoding the CNG channel. Cells were aliquoted and cryopreserved in 90% FBS/10% DMSO either 20 minutes or 18 hrs. after flow electroporation in a CL-2 processing assembly. Cells were transferred to multiwell plates immediately after thawing, and assayed following

Sensitive GPCR Assay Responses with Cryopreserved Cells

No Electroporation 🛓 Cryo. 20 min post EP Cryo. 20 hrs post EP

following large-scale electroporation and cryopreservation. HEK cells were cryopreserved 20 min. or 20 hrs. post electroporation with the ACTOne Biosensor CNG plasmid. Both sets of cells showed concentration-dependent responses to isoproterenol and NECA that were comparable to the assay performances of freshly transfected cells (Figure 4). The Y axis shows levels of fluorescence after compound addition relative to levels before compound addition. Cells that were cryopreserved at 20 min. exhibited greater assay sensitivity, reflecting the rapid kinetics of transgene expression post electroporation.

• The MaxCyte STX scalable transfection system combined with the Codex ACTOne Bionsensor technology enables rapid generation of cells for GPCR

• Assay sensitivity can be adjusted simply by altering the concentration of DNA in the electroporation reaction.

• Large scale (flow) electroporation allows users to generate cells for multiple assays in a single transfection run.

• Cells can be cryopreserved following electroporation without impacting assay performance. Users have the flexibility to run assays at their convenience, and they can be assured of consistent assay responses by aliquoting cells from a single, bulk transfection.



Tel: (301) 944-1700 info@maxcyte.com www.maxcyte.com

©2012 MaxCyte, Inc. All Rights Reserved MaxCyte and MaxCyte STX are registered trademarks and/or trademarks of MaxCyte, Inc. ACTOne is a trademark of Codex BioSolutions, Inc.